As already stated, fludarabine has been associated, as single agent, with a high incidence of AIHA in CLL, while the combination with rituximab seems protective, as well as new molecules (however most trials in LPD excluded DAT‐positive patients). The gene discussed is SLC6A3; the disease is autoimmune hemolytic anemia.